Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Phase 1 Suspended

75 enrolled

GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Phase 2 Terminated

18 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04711252 2025-10-14

SERENA-4

Phase 3 Active not recruiting

1,370 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1 Recruiting

45 enrolled

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

Clinical Trials

SERENA-6

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

TAPUR

PIKALO-1

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

SERENA-4

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors